1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Nichi-Iko rights offering to support production, biosimilar plans

 
• By Ian Haydock

The major Japanese generics firm Nichi-Iko Pharmaceutical is planning to raise an estimated JPY12.58bn ($123m) in total net proceeds from a new rights offering, with the new funds already earmarked for an array of capital investment and product development projects.

The major Japanese generics firm Nichi-Iko Pharmaceutical is planning to raise an estimated JPY12.58bn ($123m) in total net proceeds from a new rights offering, with the new funds already earmarked for an array of capital investment and product development projects.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

US-China Tariff War Pressures Pharma’s Complex Supply Chain

 
• By Lisa Takagi

Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.

AstraZeneca Logs Japan Growth Despite Price Cuts

 
• By Lisa Takagi

AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years.

Sumitomo Offloads Asia Pharma Ops To Marubeni For $480m

 
• By Ian Haydock

The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.

More from Focus On Asia

US-China Tariff War Pressures Pharma’s Complex Supply Chain

 
• By Lisa Takagi

Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.

AstraZeneca Logs Japan Growth Despite Price Cuts

 
• By Lisa Takagi

AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years.

Korean Biotech Roundup: GNT Set For First Direct Korean Biopharma IPO On Nasdaq

 
• By Jung Won Shin

GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.